Frontier of Endocrine Tumor Imaging

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 8974

Special Issue Editors

1. Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland
2. Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland
Interests: meta-analysis; PET; nuclear medicine; systematic reviews; brain tumor imaging
Special Issues, Collections and Topics in MDPI journals
Department of Nuclear Medicine, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France
Interests: nuclear medicine; PET imaging; neuroendocrine tumors; PRRT; paraganglioma; pheochromocytoma; thyroid medullary carcinoma; infection
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Endocrine tumors originate from glands or cells that produce hormones. These include thyroid, adrenal, pituitary, and cells/glands of the neuroendocrine system. Endocrine/neuroendocrine tumors can be called by different names depending on where they are located in the body, or from which endocrine cell/gland they arise.

Imaging methods may be extremely useful for diagnosis, monitoring, treatment response assessment, and for obtaining prognostic information in patients with endocrine and neuroendocrine tumors.

Imaging methods for assessing endocrine/neuroendocrine tumors are extremely varied, including conventional techniques of morphological imaging (ultrasound, computed tomography (CT), magnetic resonance imaging (MRI)), endoscopic explorations, and functional imaging techniques (positron emission tomography (PET) and scintigraphic methods).

This Special Issue aims to gather articles concerning imaging techniques in endocrine/neuroendocrine tumors.

Prof. Dr. Giorgio Treglia
Prof. Dr. Alessio Imperiale
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

12 pages, 5403 KiB  
Article
18F-Fluorocholine PET and 4D-CT in Patients with Persistent and Recurrent Primary Hyperparathyroidism
by Adrien Latge, Sophie Riehm, Michel Vix, Jacob Bani, Mihaela Ignat, Valentin Pretet, Mehdi Helali, Giorgio Treglia and Alessio Imperiale
Diagnostics 2021, 11(12), 2384; https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics11122384 - 17 Dec 2021
Cited by 12 | Viewed by 2331
Abstract
Patients with primary hyperparathyroidism (pHPT) can develop persistent (P-pHPT) or recurrent (R-pHPT) disease after parathyroidectomy. Before recommending reoperation, recurrence must be accurately identified because of the high risk of complications. Our study evaluates 18F-fluorocholine (18F-FCH) PET/CT and 4D-CT integrated in [...] Read more.
Patients with primary hyperparathyroidism (pHPT) can develop persistent (P-pHPT) or recurrent (R-pHPT) disease after parathyroidectomy. Before recommending reoperation, recurrence must be accurately identified because of the high risk of complications. Our study evaluates 18F-fluorocholine (18F-FCH) PET/CT and 4D-CT integrated in PET/4D-CT in patients with P-pHPT/R-pHPT. Patients with P-pHPT/R-pHPT investigated by 18F-FCH PET/4D-CT between May 2018 and March 2021 were retrospectively included. Forty-two patients were included, 37 of whom underwent 4D-CT. The sensitivity and detection rate (DR%) were 95% and 88% for 18F-FCH PET/CT and 70% and 63% for 4D-CT, respectively. PET/CT and 4D-CT were concordant in 18/24 glands and concordant and positive in 15/24 (63%) glands. Discordant results were obtained for 6/24 glands. The surgical success rate was 65%. PET/CT showed significantly higher sensitivity than 4D-CT. Dynamic CT allowed the identification of no additional glands missed by PET/CT, and the combination of the 2 techniques did not improve the sensitivity or DR%. 18F-FCH PET/CT appears to be a valuable technique to accurately detect hyperfunctioning parathyroid tissue in patients with P-pHPT/R-pHPT and is better than 4D-CT. Except for cases with doubtful locations of PET targets that may require 4D-CT for surgical guidance, standard nonenhanced 18F-FCH PET/CT can be effectively recommended in patients with P-pHPT/R-pHPT before reoperation. Full article
(This article belongs to the Special Issue Frontier of Endocrine Tumor Imaging)
Show Figures

Figure 1

Review

Jump to: Research, Other

15 pages, 5851 KiB  
Review
Adrenal Lesions: A Review of Imaging
by Benedetta Bracci, Domenico De Santis, Antonella Del Gaudio, Maria Carla Faugno, Allegra Romano, Mariarita Tarallo, Marta Zerunian, Gisella Guido, Michela Polici, Tiziano Polidori, Francesco Pucciarelli, Iolanda Matarazzo, Andrea Laghi and Damiano Caruso
Diagnostics 2022, 12(9), 2171; https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics12092171 - 08 Sep 2022
Cited by 4 | Viewed by 4626
Abstract
Adrenal lesions are frequently incidentally diagnosed during investigations for other clinical conditions. Despite being usually benign, nonfunctioning, and silent, they can occasionally cause discomfort or be responsible for various clinical conditions due to hormonal dysregulation; therefore, their characterization is of paramount importance for [...] Read more.
Adrenal lesions are frequently incidentally diagnosed during investigations for other clinical conditions. Despite being usually benign, nonfunctioning, and silent, they can occasionally cause discomfort or be responsible for various clinical conditions due to hormonal dysregulation; therefore, their characterization is of paramount importance for establishing the best therapeutic strategy. Imaging techniques such as ultrasound, computed tomography, magnetic resonance, and PET-TC, providing anatomical and functional information, play a central role in the diagnostic workup, allowing clinicians and surgeons to choose the optimal lesion management. This review aims at providing an overview of the most encountered adrenal lesions, both benign and malignant, including describing their imaging characteristics. Full article
(This article belongs to the Special Issue Frontier of Endocrine Tumor Imaging)
Show Figures

Figure 1

Other

Jump to: Research, Review

10 pages, 1345 KiB  
Case Report
Diagnosis and Treatment of Acute Pleural Effusion following Radioiodine Remnant Ablation Post Lobectomy for Thyroid Cancer
by Xian Qiu, Pengwen Wang, Ri Sa, Lin Cheng, Yuchen Jin, Hongjun Song and Libo Chen
Diagnostics 2022, 12(12), 2982; https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics12122982 - 28 Nov 2022
Viewed by 1194
Abstract
Radioiodine remnant ablation (RRA) was previously demonstrated to be a safe and effective alternative to completion thyroidectomy for patients with differentiated thyroid cancer (DTC). However, its side effects have not been fully investigated, particularly in patients with lobectomy. We reported a young euthyroidal [...] Read more.
Radioiodine remnant ablation (RRA) was previously demonstrated to be a safe and effective alternative to completion thyroidectomy for patients with differentiated thyroid cancer (DTC). However, its side effects have not been fully investigated, particularly in patients with lobectomy. We reported a young euthyroidal female who underwent RRA post lobectomy and lymph node dissection for papillary thyroid cancer, whose post-ablation 131I-whole-body scan accidentally showed diffuse radioiodine distribution on chest-mimicking pulmonary metastases. Immediately-added single-photon emission computed tomography/computed tomography (SPECT/CT), nevertheless, revealed a 131I-accumulating swollen left thyroid lobe and emerging pleural effusion, which relieved after short-term treatment with prednisone. In summary, acute pleural effusion ascribed to RRA-induced thoracic duct compression was reported for the first time. 131I-lobectomy-induced pleural effusion could be precisely diagnosed by SPECT/CT and efficiently manipulated via treating radiation thyroiditis with the short-term administration of corticosteroid. Full article
(This article belongs to the Special Issue Frontier of Endocrine Tumor Imaging)
Show Figures

Figure 1

Back to TopTop